Related Experiment Video
Updated: Jun 24, 2026

Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Microbiological profile of a new topical antibacterial: retapamulin ointment 1%
Nicole E Scangarella-Oman1, Ribhi M Shawar, Samuel Bouchillon
1GlaxoSmithKline, Collegeville, PA 19426, USA. nicole_e_scangarella-oman@gsk.com
Abstract:
Retapamulin is a new topical pleuromutilin antibiotic for the treatment of skin and skin-structure infections, including impetigo. In vitro studies indicate that retapamulin has a unique mode of action that minimizes the potential for target-specific cross-resistance with other antibacterials and a limited potential for resistance development. Its spectrum of activity includes the most likely causative pathogens Staphylococcus aureus and Streptococcus pyogenes. In the Global Surveillance Program, retapamulin was highly active in vitro, including against strains of S. aureus resistant to methicillin, mupirocin or fusidic acid. In clinical studies, retapamulin was noninferior to fusidic acid and oral cefalexin, achieving per-pathogen success rates of 86-99%. Topical retapamulin has a good safety profile and is associated with high patient compliance.
Insights
Retapamulin offers a novel topical treatment for skin infections like impetigo. This pleuromutilin antibiotic shows low resistance potential and high efficacy against common pathogens, including resistant strains.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- Skin and skin-structure infections (SSIs) pose a significant clinical challenge.
- Emerging antibiotic resistance necessitates novel therapeutic agents.
- Topical antibiotics are crucial for managing localized SSIs.
Purpose of the Study:
- To evaluate the efficacy and safety of retapamulin, a novel topical pleuromutilin antibiotic.
- To assess retapamulin's activity against key pathogens causing SSIs, including resistant strains.
- To compare retapamulin's performance with existing treatments.
Main Methods:
- In vitro susceptibility testing against common SSI pathogens (Staphylococcus aureus, Streptococcus pyogenes).
- Global surveillance program data analysis for in vitro activity.
- Clinical trials comparing topical retapamulin with fusidic acid and oral cefalexin.
Main Results:
- Retapamulin demonstrated high in vitro activity, including against methicillin-resistant Staphylococcus aureus (MRSA).
- Clinical studies showed retapamulin was noninferior to fusidic acid and cefalexin.
- Per-pathogen success rates ranged from 86% to 99%.
Conclusions:
- Topical retapamulin is an effective treatment for impetigo and other SSIs.
- It possesses a favorable safety profile and high patient compliance.
- Retapamulin's unique mechanism minimizes cross-resistance and resistance development potential.
Related Concept Videos
Microbiome of the Eye
The Skin Microbiota
Surface Membrane Barriers
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
Hand hygiene
Hand washing...

